Earnings Summary

Biocryst Pharmaceuticals Inc’s revenue fell -57.87% since last year same period to $3.98Mn in the Q1 2018. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated 2.21% jump in its revenue since last 3-months.

Biocryst Pharmaceuticals Inc’s net profit fell -81.29% since last year same period to $-25.78Mn in the Q1 2018. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated -31.9% fall in its net profits since last 3-months.

Biocryst Pharmaceuticals Inc’s net profit margin fell -330.28% since last year same period to -648.31% in the Q1 2018. On a quarterly growth basis, Biocryst Pharmaceuticals Inc has generated -29.05% fall in its net profit margins since last 3-months.

Biocryst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.16 - a 44.83% jump from last quarter’s estimates.

Biocryst Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.16.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Biocryst Pharmaceuticals Inc’s return on assets (ROA) stands at -0.16.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Biocryst Pharmaceuticals Inc’s return on equity (ROE) stands at -19.25.